Business Wire

VA-REGULA

30.4.2024 09:01:34 CEST | Business Wire | Press release

Share
Uber Poland Boosts Safety and Speed of Driver Verification with Regula Solutions

Regula 70X9 document readers were shipped to three Uber Verification Centers in Warsaw, Krakow, and Poznan, which serve as dedicated hubs where drivers submit their driver’s licenses and identification documents for thorough verification. The shipment was fulfilled by Regula’s Polish distributor, Korporacja Wschód (KW), whose forensic experts also provided special training on how to use the new devices.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430896042/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Regula document readers power the driver verification process for Uber Poland (Photo: Business Wire)

The Regula 70X9 became the core element of Uber’s mission to enhance their safety protocols. It allows Uber employees to perform a comprehensive set of checks to authenticate an ID. The reader automatically identifies the document type; reads the data in all the document zones, including the visual zone, MRZ (machine-readable zone), RFID (radio frequency identification) chips, and barcodes; and cross-compares the obtained text and graphic data. Plus, the supplied document readers are equipped with Automatic Authenticity Control technology. At its core are automated checks that swiftly assess the integrity of the provided documents, detecting any signs of forgery or alteration. All of the above features, together with integrated light sources, significantly reduce the risk of mistakenly verifying forged documents.

The current workflow carried out by Uber’s employees includes:

Step 1. Comparison of the documents provided by the driver with the documents uploaded in the Uber application.

Step 2. Verification of Background Check Certificate.

Step 3. Authenticity verification of passport/ID and driver’s license with the Regula 70X9 reader.

Step 4. Taking a driver’s profile picture.

Step 5. Finalizing verification in the system: data input, document upload, and profile picture upload.

“The process of personally vetting drivers has been, and continues to be, a major logistical challenge, but we believe our efforts will help improve safety in transit. Thanks to the Regula device, the first stage went very smoothly for us. This process, although lengthy, is certainly effective,” says Marcin Konrad Moczyrog, Director and Global Manager at Uber Rides, Central & Eastern Europe.

Prior to the integration of the Regula 70X9, drivers’ documents were verified by Uber’s employees, either manually or via an application based on AI algorithms. The old method had two problems: it was time-consuming, and it did not guarantee protection against high-level forgeries of documents.

“Document fraud is constantly on the rise, and since counterfeited documents are becoming more sophisticated, manual checks are no longer enough. Some inherent document security features may be verified only with special equipment or software solutions. We are honored that our devices have become the cornerstone for a revamped verification process at Uber, and are pleased to see that it’s bearing fruit,” says Maris Kaminskis, Executive Director at Regula Europe.

For additional information, please visit the website.

About Uber

Uber is a technology application connecting passengers and drivers that has revolutionized the way people travel. Since its inception in 2009, Uber has experienced exponential growth, expanding its operations to numerous cities worldwide. Uber operates in more than 10,000 cities across more than 71 countries, making it one of the largest ride-hailing platforms globally.

In Poland, Uber is available in 25 locations.

About Korporacja Wschód

Founded in 1995, Korporacja Wschód is a family-run business that has continually evolved to meet the dynamic needs of high-technology sectors. As the distributor of Regula products in Poland since 1996, we have established ourselves as a vital link in delivering technological solutions to various enforcement and security agencies. Our expertise spans the development, integration, implementation, and distribution of advanced technology equipment, catering primarily to Border Guards, Police, Military, and a range of non-governmental enterprises and institutions. Our collaboration with Regula, a leader in forensic science technologies, underscores our commitment to offering cutting-edge solutions in document verification and security.

Learn more at https://korporacjawschod.pl.

About Regula

With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed.

Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.

Learn more at regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240430896042/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye